ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.720,01
-1,47%
S&P 500
5.702,55
-0,19%
Dow Jones
42.063,36
0,09%
Euro vs US Dollar
1,11705
-0,04%
Bitcoin
63.264,97
0,10%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Arcutis Biotherapeutics Inc (ARQT)

  7. Arcutis Biotherapeutics Inc (ARQT) News

ARQT

Arcutis Biotherapeutics (ARQT)

Arcutis Biotherapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:ARQT
DatumZeitQuelleÜberschriftSymbolFirma
19/09/202414h00GlobeNewswire Inc.Arcutis Announces Publication of ZORYVE® (roflumilast) Cream 0.15% Pivotal Results from Phase 3 INTEGUMENT-1 and -2 Trials in Mild to Moderate Atopic Dermatitis in Journal of American Medical Association DermatologyNASDAQ:ARQTArcutis Biotherapeutics Inc
05/09/202423h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/09/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
05/09/202414h00GlobeNewswire Inc.Arcutis Completes Enrollment of Phase 1b Alopecia Areata Study Evaluating ARQ-255NASDAQ:ARQTArcutis Biotherapeutics Inc
03/09/202419h37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
28/08/202414h00GlobeNewswire Inc.Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.05% Show Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
22/08/202414h00GlobeNewswire Inc.Arcutis to Present at the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:ARQTArcutis Biotherapeutics Inc
15/08/202412h08IH Market NewsCisco Beats Estimates and Announces Restructuring, Canoo Rises 6%, Lulus Losses Widen, Latest in EarningsNASDAQ:ARQTArcutis Biotherapeutics Inc
15/08/202403h00GlobeNewswire Inc.CORRECTION – Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
14/08/202422h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ARQTArcutis Biotherapeutics Inc
14/08/202422h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ARQTArcutis Biotherapeutics Inc
14/08/202422h00GlobeNewswire Inc.Arcutis Announces Second Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:ARQTArcutis Biotherapeutics Inc
14/08/202411h58IH Market NewsU.S. Futures Steady After Tuesday’s Strong Recovery; CPI in FocusNASDAQ:ARQTArcutis Biotherapeutics Inc
05/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
05/08/202422h37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/08/202422h22Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/08/202422h19Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
02/08/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
01/08/202422h45Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
01/08/202422h00GlobeNewswire Inc.Arcutis to Report Second Quarter 2024 Financial Results and Host Conference Call on August 14, 2024NASDAQ:ARQTArcutis Biotherapeutics Inc
29/07/202413h35GlobeNewswire Inc.Arcutis Announces ZORYVE® U.S. Co-promote Agreement with Kowa Pharmaceuticals America, Inc.NASDAQ:ARQTArcutis Biotherapeutics Inc
29/07/202413h30GlobeNewswire Inc.Arcutis Launches ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
24/07/202422h10Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:ARQTArcutis Biotherapeutics Inc
23/07/202414h00GlobeNewswire Inc.Arcutis Submits Supplemental New Drug Application for ZORYVE® (roflumilast) Foam to the FDA for the Treatment of Scalp and Body Psoriasis in Adults and Adolescents Ages 12 and OverNASDAQ:ARQTArcutis Biotherapeutics Inc
22/07/202414h00GlobeNewswire Inc.Arcutis to Host ZORYVE® (Roflumilast) Cream 0.15% FDA Approval Call With KOLNASDAQ:ARQTArcutis Biotherapeutics Inc
09/07/202422h53GlobeNewswire Inc.FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of AgeNASDAQ:ARQTArcutis Biotherapeutics Inc
09/07/202414h00GlobeNewswire Inc.Arcutis Provides Update on sNDA for Roflumilast Cream 0.15% for Atopic DermatitisNASDAQ:ARQTArcutis Biotherapeutics Inc
03/07/202422h00GlobeNewswire Inc.Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ARQTArcutis Biotherapeutics Inc
18/06/202422h52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ARQTArcutis Biotherapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:ARQT

Kürzlich von Ihnen besucht

AMEX
XLE
Energy Select Sector SPDR
CCOM
US30
US 30
TG
NOV
Novo Nordisk
COIN
SOLUSD
Solana
COIN
ADAUSD
Cardano
NASDAQ
NVDA
NVIDIA
NYSE
DIS
Walt Disney
NYSE
NKE
Nike
AMEX
SPY
SPDR S&P 500
COIN
ETHUSD
Ethereum
USOTC
RHHBY
Roche (QX)
NYSE
MCD
McDonalds
COIN
AVAXUSD
Avalanche
NYSE
XOM
Exxon Mobil
AMEX
XLF
Financial Select Sector
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten